

Publication list (last 8 years)

as of January 2021

Prof. Dr. Walter Weder

Peer-reviewed articles (original publications)

1. Caviezel C, Guglielmetti LC, Ladan M, Hansen HJ, Perch M, Schneiter D, **Weder W**, Opitz I, Franzen D. Lung volume reduction surgery as salvage procedure after previous use of endobronchial valves. *Interact Cardiovasc Thorac Surg*. 2021 Jan 22;32(2):263-269. doi: 10.1093/icvts/ivaa261. PMID: 33280038.
2. Inci I, Schuurmans MM, Caviezel C, Hillinger S, Opitz I, Schneiter D, **Weder W**. Long-Term Outcomes of Cadaveric Lobar Lung Transplantation: An Important Surgical Option. *Ann Thorac Cardiovasc Surg*. 2021 Jan 20. doi: 10.5761/atcs.0a.20-00237. Epub ahead of print. PMID: 33473053.
3. Ferreirinha J, Caviezel C, **Weder W**, Opitz I, Inci I. Postoperative outcome of tracheal resection in benign and malignant tracheal stenosis. *Swiss Med Wkly*. 2020 Dec 30;150:w20383. doi: 10.4414/smw.2020.20383. PMID: 33378546.
4. Citak N, Guglielmetti L, Aksoy Y, Isgörücü O, Metin M, Sayar A, Opitz I, Schneiter D, **Weder W**, Inci I. Is There a Prognostic Difference Between Stage IIIA Subgroups in Lung Cancer? *Ann Thorac Surg*. 2020 Nov 26;S0003-4975(20)32015-4. doi: 10.1016/j.athoracsur.2020.10.033. Epub ahead of print. PMID: 33248991.
5. Inci I, Arni S, Iskender I, Citak N, Rodriguez JM, Weisskopf M, Opitz I, **Weder W**, Frauenfelder T, Krafft MP, Spahn DR. Functional, Metabolic and Morphologic Results of Ex Vivo Donor Lung Perfusion with a Perfluorocarbon-Based Oxygen Carrier Nanoemulsion in a Large Animal Transplantation Model. *Cells*. 2020 Nov 18;9(11):2501. doi: 10.3390/cells9112501. PMID: 33218154; PMCID: PMC7698917.
6. Lauk O, Bruestle K, Neuer T, Battilana B, Nguyen TDL, Frauenfelder T, Stahel R, **Weder W**, Curioni-Fontecedro A, Opitz I. The Impact on Outcome by Adding Bevacizumab to Standard Induction Chemotherapy Prior to Mesothelioma Surgery: A Retrospective Single Center Analysis. *Front Oncol*. 2020 Nov 13;10:588563. doi: 10.3389/fonc.2020.588563. PMID: 33304848; PMCID: PMC7693632.
7. Caviezel C, Froehlich T, Schneiter D, Muehlematter U, Frauenfelder T, Guglielmetti LC, Opitz I, **Weder W**. Identification of target zones for lung volume reduction surgery using three-dimensional computed tomography rendering. *ERJ Open Res*. 2020 Sep 14;6(3):00305-2020. doi: 10.1183/23120541.00305-2020. PMID: 32963992; PMCID: PMC7487346.
8. Gachechiladze M, Škarda J, Skanderová D, Überall I, Kolek V, Smičkova P, Vojta P, Vbrková J, Hajdúch M, Shani I, Kolář Z, Stahel R, **Weder W**, Rulle U, Soltermann A, Joerger M. Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma. *Lung Cancer*. 2020 Sep;147:30-38. doi: 10.1016/j.lungcan.2020.06.025. Epub 2020 Jun 23. PMID: 32653671.
9. Xu Y, Guo Z, Liu R, Wang H, Wang S, **Weder W**, Pan Y, Wu J, Zhao H, Luo Q, Tan Q. Bioengineered carina reconstruction using In-Vivo Bioreactor technique in human: proof of concept study. *Transl Lung Cancer Res*. 2020 Jun;9(3):705-712. doi: 10.21037/tlcr-20-534. PMID: 32676332; PMCID: PMC7354144.

10. Opitz I, Patella M, Payrard L, Perentes JY, Inderbitzi R, Gelpke H, Schulte S, Diezi M, Gonzalez M, Krueger T, **Weder W**. Prognostic factors of oligometastatic non-small-cell lung cancer following radical therapy: a multicentre analysis. *Eur J Cardiothorac Surg*. 2020 Jun 1;57(6):1166-1172. doi: 10.1093/ejcts/ezz384. PMID: 32011665.
11. Inci I, Benker M, Çitak N, Schneiter D, Caviezel C, Hillinger S, Opitz I, **Weder W**. Complex sleeve lobectomy has the same surgical outcome when compared with conventional lobectomy in patients with lung cancer. *Eur J Cardiothorac Surg*. 2020 May 1;57(5):860-866. doi: 10.1093/ejcts/ezz357. PMID: 31919516.
12. Iskender I, Arni S, Maeyashiki T, Citak N, Sauer M, Rodriguez JM, Frauenfelder T, Opitz I, **Weder W**, Inci I. Perfusate adsorption during ex vivo lung perfusion improves early post-transplant lung function. *J Thorac Cardiovasc Surg*. 2021 Feb;161(2):e109-e121. doi: 10.1016/j.jtcvs.2019.12.128. Epub 2020 Feb 20. PMID: 32201002.
13. Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, **Weder W**, Yatabe Y. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. *J Thorac Oncol*. 2020 May;15(5):709-740. doi: 10.1016/j.jtho.2020.01.005. Epub 2020 Jan 28. PMID: 32004713.
14. Thunnissen E, Kerr KM, Dafni U, Bubendorf L, Finn SP, Soltermann A, Biernat W, Cheney R, Verbeken E, Warth A, Marchetti A, Speel EM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Tsourti Z, Geiger T, Kammler R, Peters S, Stahel RA; European Thoracic Oncology Platform Lungscape Consortium. Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort. *Mod Pathol*. 2020 May;33(5):792-801. doi: 10.1038/s41379-019-0383-9. Epub 2019 Nov 18. PMID: 31740722.
15. Grande B, Oechslin P, Schlaepfer M, Seifert B, Inci I, Opitz I, Spahn DR, **Weder W**, Zalunardo M. Predictors of blood loss in lung transplant surgery—a single center retrospective cohort analysis. *J Thorac Dis*. 2019 Nov;11(11):4755-4761. doi: 10.21037/jtd.2019.10.61. PMID: 31903265; PMCID: PMC6940236.
16. Okonska A, Bühler S, Rao V, Ronner M, Blijlevens M, van der Meulen-Muileman IH, de Menezes RX, Wipplinger M, Oehl K, Smit EF, **Weder W**, Stahel RA, Penengo L, van Beusechem VW, Felley-Bosco E. Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition. *Mol Cancer Ther*. 2020 Feb;19(2):552-563. doi: 10.1158/1535-7163.MCT-19-0356. Epub 2019 Oct 16. PMID: 31619462.
17. Stamatis G, Leschber G, Schwarz B, Brintrup DL, Ose C, Weinreich G, Passlick B, Hecker E, Kugler C, Dienemann H, Krbek T, Eggeling S, Hatz R, Müller MR, **Weder W**, Aigner C, Jöckel KH. Perioperative course and quality of life in a prospective randomized multicenter phase III trial, comparing standard lobectomy versus anatomical segmentectomy in patients with non-small cell lung cancer up to 2 cm, stage IA (7th edition of TNM staging system). *Lung Cancer*. 2019 Dec;138:19-26. doi: 10.1016/j.lungcan.2019.09.021. Epub 2019 Sep 27. PMID: 31606521.
18. Schröder C, Opitz I, Guckenberger M, Stahel R, **Weder W**, Förster R, Andratschke N, Lauk O. Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy. *Front Oncol*. 2019 Sep 26;9:961. doi: 10.3389/fonc.2019.00961. PMID: 31616640; PMCID: PMC6775182.
19. Yamada Y, Kaplan T, Soltermann A, Schmitt-Opitz I, Schneiter D, **Weder W**, Inci I. Surgical Outcomes and Risk Analysis of Primary Pulmonary Sarcoma. *Thorac Cardiovasc Surg*. 2019 Sep 9. doi: 10.1055/s-0039-1695784. Epub ahead of print. PMID: 31499540.
20. Opitz I, Lauk O, Meerang M, Jetter A, Aeschlimann B, Seifert B, Günther D, Stahel RA, **Weder W**. Intracavitary cisplatin-fibrin chemotherapy after surgery for malignant pleural mesothelioma: A phase I trial. *J Thorac Cardiovasc Surg*. 2019 Aug 22; S0022-5223(19)31613-7. doi: 10.1016/j.jtcvs.2019.07.073. Epub ahead of print. PMID: 31590949.

21. Buschmann J, Yamada Y, Schulz-Schönhagen K, Hess SC, Stark WJ, Opelz C, Bürgisser GM, **Weder W**, Jungraithmayr W. Hybrid nanocomposite as a chest wall graft with improved integration by adipose-derived stem cells. *Sci Rep*. 2019 Jul 29;9(1):10910. doi: 10.1038/s41598-019-47441-9.
22. Brosseau C, Danger R, Durand M, Durand E, Foureau A, Lacoste P, Tissot A, Roux A, Reynaud-Gaubert M, Kessler R, Mussot S, Dromer C, Brugière O, Mornex JF, Guillemain R, Claustre J, Magnan A, Brouard S; COLT and SysCLAD Consortia. Blood CD9+B cell, a biomarker of bronchiolitis obliterans syndrome after lung transplantation. *Am J Transplant*. 2019 Jul 15. doi: 10.1111/ajt.15532.
23. Lacour M, Hiltbrunner S, Lee SY, Soltermann A, Rushing EJ, Soldini D, **Weder W**, Curioni-Fontecedro A. Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non-small Cell Lung Cancer Recurrence. *Clin Lung Cancer*. 2019 Sep;20(5):391-396. doi: 10.1016/j.clcc.2019.05.013. Epub 2019 Jun 5.
24. Riesterer O, Frank Ciernik I, Stahel RA, Xyrafas A, Aebersold DM, Plasswilm L, Mahmut Ozsahin E, Zwahlen DR, Nackaerts K, Zimmermann F, Sabrina Stark L, **Weder W**, Krayenbuehl J; Swiss Group for Clinical Cancer Research (SAKK). Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial. *Radiother Oncol*. 2019 Sep;138:121-125. doi: 10.1016/j.radonc.2019.05.024. Epub 2019 Jun 25.
25. Kresoja-Rakic J, Szepechcinski A, Kirschner MB, Ronner M, Minatel B, Martinez VD, Lam WL, **Weder W**, Stahel R, Früh M, Cerciello F, Felley-Bosco E. miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery. *Noncoding RNA*. 2019 Jun 17;5(2). pii: E41. doi: 10.3390/ncrna5020041.
26. Kerr KM, Thunnissen E, Dafni U, Finn SP, Bubendorf L, Soltermann A, Verbeken E, Biernat W, Warth A, Marchetti A, Speel EM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Radonic T, Wilson J, De Luca G, Gray SG, Cheney R, Savic S, Martorell M, Muley T, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dziadziuszko R, Vansteenkiste J, **Weder W**, Polydoropoulou V, Geiger T, Kammler R, Peters S, Stahel R; Lungscape Consortium. A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. *Lung Cancer*. 2019 May;131:95-103. doi: 10.1016/j.lungcan.2019.03.012. Epub 2019 Mar 15.
27. Muehlematter UJ, Caviezel C, Martini K, Messerli M, Vokinger KN, Wetzler IR, Tutic-Horn M, **Weder W**, Frauenfelder T. Applicability of color-coded computed tomography images in lung volume reduction surgery planning. *J Thorac Dis*. 2019 Mar;11(3):766-776. doi: 10.21037/jtd.2019.02.36.
28. Caviezel C, Schuepbach R, Grande B, Opitz I, Zalunardo M, **Weder W**, Hillinger S. Establishing a non-intubated thoracoscopic surgery programme for bilateral uniportal sympathectomy. *Swiss Med Wkly*. 2019 Apr 17;149:w20064. doi: 10.4414/smw.2019.20064. eCollection 2019 Apr 8.
29. Curioni-Fontecedro A, Perentes JY, Gelpke H, Xyrafas A, Bouchaab H, Mach N, Matzinger O, Stojcheva N, Früh M, **Weder W**, Cathomas R, Gargiulo P, Bubendorf L, Pless M, Betticher D, Peters S; Swiss Group of Clinical Cancer Research (SAKK). Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08). *Br J Cancer*. 2019 May;120(10):968-974. doi: 10.1038/s41416-019-0447-0. Epub 2019 Apr 16.
30. van Geffen WH, Slebos DJ, Herth FJ, Kemp SV, **Weder W**, Shah PL. Surgical and endoscopic interventions that reduce lung volume for emphysema: a systemic review and meta-analysis. *Lancet Respir Med*. 2019 Apr;7(4):313-324. doi: 10.1016/S2213-2600(18)30431-4. Epub 2019 Feb 8.
31. Jang JH, Janker F, De Meester I, Arni S, Borgeaud N, Yamada Y, Gil Bazo I, **Weder W**, Jungraithmayr W. The CD26/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity. *Carcinogenesis*. 2019 Jan 29. doi: 10.1093/carcin/bgz009. [Epub ahead of print]
32. Román M, López I, Guruceaga E, Baraibar I, Ecay M, Collantes M, Nadal E, Vallejo A, Cadenas S, Miguel ME, Jang JH, Martin-Uriz PS, Castro-Labrador L, Vilas-Zornoza A, Lara-Astiaso D, Ponz-Sarvisé M, Rolfo C, Santos ES, Raez LE, Taverna S, Behrens C, **Weder W**, Wistuba II, Vicent S, Gil-Bazo I. Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network. *Cancer Res*. 2019 Feb 1;79(3):625-638. doi: 10.1158/0008-5472.CAN-18-1479. Epub 2018 Dec 18.

33. Maeyashiki T, Jang JH, Janker F, Yamada Y, Inci I, **Weder W**, Piegeler T, Jungraithmayr W. The Amide Local Anesthetic Ropivacaine Attenuates Acute Rejection After Allogeneic Mouse Lung Transplantation. *Lung*. 2019 Feb 9. doi: 10.1007/s00408-019-00197-5. [Epub ahead of print]
34. Ruffini E, Guerrera F, Brunelli A, Passani S, Pellicano D, Thomas P, Van Raemdonck D, Rocco G, Venuta F, **Weder W**, Detterbeck F, Falcoz PE. Report from the European Society of Thoracic Surgeons prospective thymic database 2017: a powerful resource for a collaborative global effort to manage thymic tumours. *Eur J Cardiothorac Surg*. 2019 Apr 1;55(4):601-609. doi: 10.1093/ejcts/ezy448.
35. Pompeo E, Rogliani P, Atinkaya C, Guerrera F, Ruffini E, Iñiguez-Garcia MA, Peer M, Voltolini L, Caviezel C, **Weder W**, Opitz I, Cavalli F, Sorge R. Nonintubated surgical biopsy of undetermined interstitial lung disease: a multicentre outcome analysis. *Interact Cardiovasc Thorac Surg*. 2018 Dec 1. doi: 10.1093/icvts/ivy320. [Epub ahead of print]
36. Früh M, Betticher DC, Stupp R, Xyrafas A, Peters S, Ris HB, Mirimanoff RO, Ochsenbein AF, Schmid R, Matzinger O, Stahel RA, **Weder W**, Guckenberger M, Rothschild SI, Lardinois D, Mach N, Mark M, Gautschi O, Thierstein S, Biaggi Rudolf C, Pless M; Swiss Group for Clinical Cancer Research (SAKK). Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). *J Thorac Oncol*. 2019 Jan;14(1):115-123. doi: 10.1016/j.jtho.2018.09.011. Epub 2018 Sep 26.
37. Rulle U, Tsourti Z, Casanova R, Deml KF, Verbeken E, Thunnissen E, Warth A, Cheney R, Sejda A, Speel EJ, Madsen LB, Nonaka D, Navarro A, Sansano I, Marchetti A, Finn SP, Monkhorst K, Kerr KM, Haberecker M, Wu C, Zygoura P, Kammler R, Geiger T, Gendreau S, Schulze K, Vrugt B, Wild P, Moch H, **Weder W**, Ciftlik AT, Dafni U, Peters S, Bubendorf L, Stahel RA, Soltermann A. Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry - Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort. *J Thorac Oncol*. 2018 Dec;13(12):1851-1863. doi: 10.1016/j.jtho.2018.08.2034. Epub 2018 Sep 18.
38. Caviezel C, von Rotz J, Schneiter D, Inci I, Hillinger S, Opitz I, **Weder W**. Improved postoperative lung function after sublobar resection of non-small-cell lung cancer combined with lung volume reduction surgery in patients with advanced emphysema. *J Thorac Dis*. 2018 Aug;10(Suppl 23):S2704-S2710. doi: 10.21037/jtd.2018.06.79.
39. Tallón de Lara P, Cecconi V, Hiltbrunner S, Yagita H, Friess M, Bode B, Opitz I, Vrugt B, **Weder W**, Stolzmann P, Felley-Bosco E, Stahel RA, Tischler V, Britschgi C, Soldini D, van den Broek M, Curioni-Fontecedro A. Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients. *Clin Cancer Res*. 2018 Dec 15;24(24):6345-6354. doi: 10.1158/1078-0432.CCR-18-1231. Epub 2018 Aug 28.
40. Martini K, Caviezel C, Schneiter D, Milanese G, Opitz I, **Weder W**, Frauenfelder T. Dynamic magnetic resonance imaging as an outcome predictor for lung-volume reduction surgery in patients with severe emphysema. *Eur J Cardiothorac Surg*. 2018 Aug 13. doi: 10.1093/ejcts/ezy277. [Epub ahead of print]
41. Janker F, **Weder W**, Jang JH, Jungraithmayr W. Preclinical, non-genetic models of lung adenocarcinoma: a comparative survey. *Oncotarget*. 2018 Jul 17;9(55):30527-30538. doi: 10.18632/oncotarget.25668. eCollection 2018 Jul 17
42. Sulser P, Lehmann K, Schuurmans MM, **Weder W**, Inci I. Early and late abdominal surgeries after lung transplantation: incidence and outcome. *Interact Cardiovasc Thorac Surg*. 2018 May 28. doi: 10.1093/icvts/ivy172. [Epub ahead of print]
43. Gulati P, Rühl J, Kannan A, Pircher M, Schuberth P, Nytko KJ, Pruschy M, Sulser S, Haefner M, Jensen S, Soltermann A, Jungraithmayr W, Eisenring M, Winder T, Samaras P, Tabor A, Stenger R, Stupp R, **Weder W**, Renner C, Münz C, Petrusch U. Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice. *Clin Cancer Res*. 2018 May 10. doi: 10.1158/1078-0432.CCR-17-1788.
44. Cottini SR, Brandi G, Pagnamenta A, **Weder W**, Schuepbach RA, Béchir M, Huber LC, Benden C. Pulmonary hypertension is not a risk factor for grade 3 primary graft dysfunction after lung transplantation. *Clin Transplant*. 2018 May;32(5):e13251.

45. Caviezel C, Aruldas C, Franzen D, Ulrich S, Inci I, Schneiter D, **Weder W**, Opitz I. Lung volume reduction surgery in selected patients with emphysema and pulmonary hypertension. *Eur J Cardiothorac Surg*. 2018 Mar 12. doi: 10.1093/ejcts/ezy092. [Epub ahead of print]
46. George J, Walter V, Peifer M, Alexandrov LB, Seidel D, Leenders F, Maas L, Müller C, Dahmen I, Delhomme TM, Ardin M, Leblay N, Byrnes G, Sun R, De Reynies A, McLeer-Florin A, Bosco G, Malchers F, Menon R, Altmüller J, Becker C, Nürnberg P, Achter V, Lang U, Schneider PM, Bogus M, Soloway MG, Wilkerson MD, Cun Y, McKay JD, Moro-Sibilot D, Brambilla CG, Lantuejoul S, Lemaitre N, Soltermann A, **Weder W**, Tischler V, Brustugun OT, Lund-Iversen M, Helland Å, Solberg S, Ansén S, Wright G, Solomon B, Roz L, Pastorino U, Petersen I, Clement JH, Sängler J, Wolf J, Vingron M, Zander T, Perner S, Travis WD, Haas SA, Olivier M, Foll M, Büttner R, Hayes DN, Brambilla E, Fernandez-Cuesta L, Thomas RK. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. *Nat Commun*. 2018 Mar 13;9(1):1048.
47. Oehl K, Kresoja-Rakic J, Opitz I, Vrugt B, **Weder W**, Stahel R, Wild P, Felley-Bosco E. Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression. *Front Oncol*. 2018 Feb 23;8:40.
48. Pavic M, Bogowicz M, Würms X, Glatz S, Finazzi T, Riesterer O, Roesch J, Rudofsky L, Friess M, Veit-Haibach P, Huellner M, Opitz I, **Weder W**, Frauenfelder T, Guckenberger M, Tanadini-Lang S. Influence of inter-observer delineation variability on radiomics stability in different tumor sites. *Acta Oncol*. 2018 Mar 7:1-5.
49. Xia D, Casanova R, Machiraju D, McKee TD, **Weder W**, Beck AH, Soltermann A. Computationally-Guided Development of a Stromal Inflammation Histologic Biomarker in Lung Squamous Cell Carcinoma. *Sci Rep*. 2018 Mar 2;8(1):3941
50. Arni S, de Wijn R, Garcia-Villegas R, Bitanirhwe BKY, Caviezel C, **Weder W**, Hillinger S. A strategy to analyse activity-based profiling of tyrosine kinase substrates in OCT-embedded lung cancer tissue. *Anal Biochem*. 2018 Apr 15;547:77-83.
51. Danger R, Royer PJ, Reboulleau D, Durand E, Loy J, Tissot A, Lacoste P, Roux A, Reynaud-Gaubert M, Gomez C, Kessler R, Mussot S, Dromer C, Brugière O, Mornex JF, Guillemain R, Dahan M, Knoop C, Botturi K, Foureau A, Pison C, Koutsokera A, Nicod LP, Brouard S, Magnan A; COLT and SysCLAD Consortia. Blood Gene Expression Predicts Bronchiolitis Obliterans Syndrome. *Front Immunol*. 2018 Jan 11;8:1841.
52. Yamada Y, Langner T, Inci I, Benden C, Schuurmans M, **Weder W**, Jungraithmayr W. Impact of human leukocyte antigen mismatch on lung transplant outcome. *Interact Cardiovasc Thorac Surg*. 2018 Jan 2. doi: 10.1093/icvts/ivx412. [Epub ahead of print]
53. Caviezel C, Schaffter N, Schneiter D, Franzen D, Inci I, Opitz I, **Weder W**. Outcome After Lung Volume Reduction Surgery in Patients With Severely Impaired Diffusion Capacity. *Ann Thorac Surg*. 2018 Feb;105(2):379-385
54. Letovanec I, Finn S, Zygoura P, Smyth P, Soltermann A, Bubendorf L, Speel EJ, Marchetti A, Nonaka D, Monkhorst K, Hager H, Martorell M, Sejda A, Cheney R, Hernandez-Losa J, Verbeken E, **Weder W**, Savic S, Di Lorito A, Navarro A, Filip E, Warth A, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dienemann H, Dziadziuszko R, Vansteenkiste J, O'Brien C, Geiger T, Sherlock J, Schageman J, Dafni U, Kammler R, Kerr K, Thunnissen E, Stahel R, Peters S; European Thoracic Oncology Platform Lungscape Consortium. Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. *J Thorac Oncol*. 2018 Mar;13(3):413-425.
55. Brüstle K, Zachariassen K, Vrugt B, Frauenfelder T, **Weder W**, Franzen D. Acute pulmonary embolism and multiple pulmonary nodules mimicking metastatic disease. *Thorax*. 2018 Feb;73(2):193-194.
56. Mouraux S, Bernasconi E, Pattaroni C, Koutsokera A, Aubert JD, Claustre J, Pison C, Royer PJ, Magnan A, Kessler R, Benden C, Soccal PM, Marsland BJ, Nicod LP; SysCLAD Consortium. Airway microbiota signals anabolic and catabolic remodeling in the transplanted lung. *J Allergy Clin Immunol*. 2018 Feb;141(2):718-729.e7.

57. Kerr KM, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, Finn S, Biernat W, Vliegen L, Losa JH, Marchetti A, Cheney R, Warth A, Speel EJ, Blackhall F, Monkhorst K, Jantus Lewintre E, Tischler V, Clark C, Bertran-Alamillo J, Meldgaard P, Gately K, Wrona A, Vandenberghe P, Filip E, De Luca G, Savic S, Muley T, Smit EF, Dingemans AC, Priest L, Baas P, Camps C, **Weder W**, Polydoropoulou V, Geiger TR, Kammler R, Sumiyoshi T, Molina MA, Shames DS, Stahel RA, Peters S; ETOP Lungscape Consortium. Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project. *Ann Oncol.* 2018 Jan 1;29(1):200-208.
58. Klikovits T, Stockhammer P, Laszlo V, Dong Y, Hoda MA, Ghanim B, Opitz I, Frauenfelder T, Nguyen-Kim TDL, **Weder W**, Berger W, Grusch M, Aigner C, Klepetko W, Dome B, Renyi-Vamos F, Oehler R, Hegedus B. Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma. *Sci Rep.* 2017 Nov 28;7(1):16456.
59. Cosgun T, Tomaszek S, Opitz I, Wilhelm M, Schuurmans MM, **Weder W**, Inci I. Single-center experience with intraoperative extracorporeal membrane oxygenation use in lung transplantation. *Int J Artif Organs.* 2017 Oct 9:0.
60. Yamada Y, Iskender I, Arni S, Hillinger S, Cosgun T, Yu K, Jungraithmayr W, Cesarovic N, **Weder W**, Inci I. Ex vivo treatment with inhaled N-acetylcysteine in porcine lung transplantation. *J Surg Res.* 2017 Oct;218:341-347
61. Arni S, Le THN, de Wijn R, Garcia-Villegas R, Dankers M, **Weder W**, Hillinger S. Ex vivo multiplex profiling of protein tyrosine kinase activities in early stages of human lung adenocarcinoma. *Oncotarget.* 2017 Aug 2;8(40):68599-68613.
62. Inci I, Iskender I, Ehrsam J, Caviezel C, Hillinger S, Opitz I, Schneiter D, **Weder W**. Previous lung volume reduction surgery does not negatively affect survival after lung transplantation. *Eur J Cardiothorac Surg.* 2018 Mar 1;53(3):596-602.
63. Buschmann J, Balli E, Hess SC, Stark WJ, Cinelli P, Märsmann S, Welti M, **Weder W**, Jungraithmayr W. Effects of seeding adipose-derived stem cells on electrospun nanocomposite used as chest wall graft in a murine model. *Injury.* 2017 Oct;48(10):2080-2088.
64. Yamada Y, Windirsch K, Dubs L, Kenkel D, Jang JH, Inci I, Boss A, Martinu T, Vanaudenaerde B, **Weder W**, Jungraithmayr W. Chronic Airway Fibrosis in Orthotopic Mouse Lung Transplantation Models - An Experimental Reappraisal. *Transplantation.* 2018 Feb;102(2):e49-e58
65. Ehrsam JP, Benden C, Seifert B, Opitz I, Schneiter D, **Weder W**, Inci I. Lung transplantation in the elderly: Influence of age, comorbidities, underlying disease, and extended criteria donor lungs. *J Thorac Cardiovasc Surg.* 2017 Jul 29. pii: S0022-5223(17)31573-8.
66. Cosgun T, Iskender I, Yamada Y, Arni S, Lipiski M, van Tilburg K, **Weder W**, Inci I. Ex vivo administration of trimetazidine improves post-transplant lung function in pig model. *Eur J Cardiothorac Surg.* 2017 Jul 1;52(1):171-177
67. Franzen D, Schneiter D, **Weder W**, Kohler M. Impact of sedation technique on the diagnostic accuracy of endobronchial ultrasound-guided transbronchial needle aspiration. *Endosc Ultrasound.* 2017 Jul-Aug;6(4):257-263.
68. Yamada Y, Laube I, Jang JH, Bonvini JM, Inci I, **Weder W**, Beck Schimmer B, Jungraithmayr W. Sevoflurane preconditioning protects from posttransplant injury in mouse lung transplantation. *J Surg Res.* 2017 Jun 15;214:270-277.
69. Kresoja-Rakic J, Sulemani M, Kirschner MB, Ronner M, Reid G, Kao S, Schwaller B, **Weder W**, Stahel RA, Felley-Bosco E. Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma. *Front Genet.* 2017 May 29;8:70
70. Iskender I, Cosgun T, Arni S, Trinkwitz M, Fehlings S, Yamada Y, Cesarovic N, Yu K, Frauenfelder T, Jungraithmayr W, **Weder W**, Inci I. Cytokine filtration modulates pulmonary metabolism and edema formation during ex vivo lung perfusion. *J Heart Lung Transplant.* 2017 May 20. pii: S1053-2498(17)31802-8. doi: 10.1016/j.healun.2017.05.021. [Epub ahead of print]

71. Castañón E, Soltermann A, López I, Román M, Ecay M, Collantes M, Redrado M, Baraibar I, López-Picazo JM, Rolfo C, Vidal-Vanaclocha F, Raez L, **Weder W**, Calvo A, Gil-Bazo I. The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment of the pre-metastatic niche. *Cancer Lett.* 2017 Aug 28;402:43-51.
72. Steiger S, Arvanitakis M, Sick B, **Weder W**, Hillinger S, Burger IA. Analysis of prognostic values of various PET metrics in preoperative FDG PET for early stage bronchial carcinoma for progression free and overall survival: significantly increased glycolysis is a predictive factor. *J Nucl Med.* 2017 May 10. pii: jnumed.117.189894. doi: 10.2967/jnumed.117.189894. [Epub ahead of print]
73. Kostron A, Friess M, Inci I, Hillinger S, Schneiter D, Gelpke H, Stahel R, Seifert B, **Weder W**, Opitz I. Propensity matched comparison of extrapleural pneumonectomy and pleurectomy/decortication for mesothelioma patients. *Interact Cardiovasc Thorac Surg.* 2017 May 1;24(5):740-746.
74. Moser B, Fadel E, Fabre D, Keshavjee S, de Perrot M, Thomas P, Brioude G, Van Raemdonck D, Viskens S, Lang-Lazdunski L, Bille A, **Weder W**, Jungraithmayr W, Ruffini E, Guerrero F, Gómez de Antonio D, Liberman M, Novoa N, Scarci M, Janik S, Klepetko W. Surgical therapy of thymic tumours with pleural involvement: an ESTS Thymic Working Group Project. *Eur J Cardiothorac Surg.* 2017 Aug 1;52(2):346-355.
75. Parrotta R, Okonska A, Ronner M, **Weder W**, Stahel R, Penengo L, Felley-Bosco E. A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair. *J Thorac Oncol.* 2017 Aug;12(8):1309-1319.
76. Casanova R, Xia D, Rulle U, Nanni P, Grossmann J, Vrugt B, Wettstein R, Ballester R, Astolfo A, **Weder W**, Moch H, Stampanoni M, Beck AH, Soltermann A. Morphoproteomic Characterization of Lung Squamous Cell Carcinoma Fragmentation, a Histological Marker of Increased Tumor Invasiveness. *Cancer Res.* 2017 May 15;77(10):2585-2593.
77. Tutic-Horn M, Gambazzi F, Rocco G, Mosimann M, Schneiter D, Opitz I, Martucci N, Hillinger S, **Weder W**, Jungraithmayr W. Curative resection for lung cancer in octogenarians is justified. *J Thorac Dis.* 2017 Feb;9(2):296-302.
78. Gachechiladze M, Škarda J, Kolek V, Grygárková I, Langová K, Bouchal J, Kolář Z, Baty F, Stahel R, **Weder W**, Soltermann A, Joerger M. Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients. *Lung Cancer.* 2017 Mar;105:31-38.
79. Jang JH, Yamada Y, Janker F, De Meester I, Baerts L, Vliegen G, Inci I, Chatterjee S, **Weder W**, Jungraithmayr W. Anti-inflammatory effects on ischemia/reperfusion-injured lung transplants by the cluster of differentiation 26/dipeptidylpeptidase 4 (CD26/DPP4) inhibitor vildagliptin. *J Thorac Cardiovasc Surg.* 2017 Mar;153(3):713-724
80. Pass H, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, Asamura H, Waller D, Edwards J, **Weder W**, Hoffmann H, van Meerbeeck JP, Nowak A, Rusch VW; IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions. The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation. *J Thorac Oncol.* 2016 Dec;11(12):2082-2088.
81. Leisibach P, Schneiter D, Soltermann A, Yamada Y, **Weder W**, Jungraithmayr W. Prognostic value of immunohistochemical markers in malignant thymic epithelial tumors. *J Thorac Dis.* 2016 Sep;8(9):2580-2591.
82. Schmid FA, Inci I, Bürgi U, Hillinger S, Schneiter D, Opitz I, Huber LC, Isenring BD, Jungraithmayr W, Schuurmans MM, **Weder W**, Benden C. Favorable outcome of children and adolescents undergoing lung transplantation at a European adult center in the new era. *Pediatr Pulmonol.* 2016 Nov;51(11):1222-1228
83. Rice D, Chansky K, Nowak A, Pass H, Kindler H, Shemanski L, Opitz I, Call S, Hasegawa S, Kernstine K, Atinkaya C, Rea F, Nafteux P, Rusch VW; Mesothelioma Domain of the IASLC Staging and Prognostic Factors Committee, advisory boards and participating institutions. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. *J Thorac Oncol.* 2016 Dec;11(12):2100-2111.

84. Nowak AK, Chansky K, Rice DC, Pass HI, Kindler HL, Shemanski L, Billé A, Rintoul RC, Batirel HF, Thomas CF, Friedberg J, Cedres S, de Perrot M, Rusch VW; Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. *J Thorac Oncol*. 2016 Dec;11(12):2089-2099
85. Rusch VW, Chansky K, Kindler HL, Nowak AK, Pass HI, Rice DC, Shemanski L, Galateau-Sallé F, McCaughan BC, Nakano T, Ruffini E, van Meerbeeck JP, Yoshimura M; IASLC Staging and Prognostic Factors Committee, advisory boards, and participating institutions. The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. *J Thorac Oncol*. 2016 Dec;11(12):2112-2119.
86. Niedzwiecki M, Yamada Y, Inci I, **Weder W**, Jungraithmayr W. Decrease of Airway Allergies After Lung Transplantation Is Associated With Reduced Basophils and Eosinophils. *Transplant Proc*. 2016 Jul-Aug;48(6):2140-6.
87. Meerang M, Bérard K, Friess M, Bitanihirwe BK, Soltermann A, Vrugt B, Felley-Bosco E, Bueno R, Richards WG, Seifert B, Stahel R, **Weder W**, Opitz I. Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma. *Mol Oncol*. 2016 Oct;10(8):1255-65.
88. Hoda MA, Dong Y, Rozsas A, Klikovits T, Laszlo V, Ghanim B, Stockhammer P, Ozsvar J, Jakopovic M, Samarzija M, Brcic L, Bendek M, Szirtes I, Reid G, Kirschner MB, Kao SC, Opitz I, **Weder W**, Frauenfelder T, Nguyen-Kim TD, Aigner C, Klepetko W, van Zandwijk N, Berger W, Dome B, Grusch M, Hegedus B. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study. *Eur J Cancer*. 2016 Aug;63:64-73.
89. Beck-Schimmer B, Bonvini JM, Braun J, Seeberger M, Neff TA, Risch TJ, Stüber F, Vogt A, **Weder W**, Schneider D, Filipovic M, Puhan M. Which Anesthesia Regimen Is Best to Reduce Morbidity and Mortality in Lung Surgery?: A Multicenter Randomized Controlled Trial. *Anesthesiology*. 2016 Aug;125(2):313-21.
90. Rothschild SI, Zippelius A, Prince SS, Gonzalez M, **Weder W**, Xyrafas A, Rusterholz C, Pless M. 129TiP: SAKK 16/14 - anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC). A multicenter single-arm phase II trial. *J Thorac Oncol*. 2016 Apr;11(4 Suppl):S112. doi: 10.1016/S1556-0864(16)30242-8. Epub 2016 Apr 15
91. Filosso PL, Yao X, Ruffini E, Ahmad U, Antonicelli A, Huang J, Guerrera F, Venuta F, van Raemdonck D, Travis W, Lucchi M, Rimner A, Thomas P, **Weder W**, Rocco G, Detterbeck F, Korst R. Comparison of outcomes between neuroendocrine thymic tumours and other subtypes of thymic carcinomas: a joint analysis of the European Society of Thoracic Surgeons and the International Thymic Malignancy Interest Group. *Eur J Cardiothorac Surg*. 2016 Oct;50(4):766-771.
92. Martini K, Meier A, Opitz I, **Weder W**, Veit-Haibach P, Stahel RA, Frauenfelder T. Diagnostic accuracy of sequential co-registered PET+MR in comparison to PET/CT in local thoracic staging of malignant pleural mesothelioma. *Lung Cancer*. 2016 Apr;94:40-5.
93. Pecoraro Y, Tsushima Y, Opitz I, Benden C, Schüpbach R, Lenherr R, Jungraithmayr W, **Weder W**, Inci I. Impact of time interval between donor brain death and cold preservation on long-term outcome in lung transplantation. *Eur J Cardiothorac Surg*. 2016 Aug;50(2):264-8.
94. Kresoja-Rakic J, Kapaklikaya E, Ziltener G, Dalcher D, Santoro R, Christensen BC, Johnson KC, Schwaller B, **Weder W**, Stahel RA, Felley-Bosco E. Identification of cis- and trans-acting elements regulating calretinin expression in mesothelioma cells. *Oncotarget*. 2016 Apr 19;7(16):21272-86.
95. Meerang M, Bérard K, Felley-Bosco E, Lauk O, Vrugt B, Boss A, Kenkel D, Broggini-Tenzer A, Stahel RA, Arni S, **Weder W**, Opitz I. Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma. *Mol Cancer Ther*. 2016 May;15(5):1095-105
96. Yamada Y, Jang JH, De Meester I, Baerts L, Vliegen G, Inci I, Yoshino I, **Weder W**, Jungraithmayr W. CD26 costimulatory blockade improves lung allograft rejection and is associated with enhanced interleukin-10 expression. *J Heart Lung Transplant*. 2016 Apr;35(4):508-17

97. Cottini SR, Ehlers UE, Pagnamenta A, Brandi G, **Weder W**, Schuepbach RA, Béchir M, Benden C. Pretransplant dyslipidaemia influences primary graft dysfunction after lung transplantation. *Interact Cardiovasc Thorac Surg*. 2016 Apr;22(4):402-5.
98. Seiler A, Jenewein J, Martin-Soelch C, Goetzmann L, Inci I, **Weder W**, Schuurmans MM, Benden C, Brucher A, Klaghofer R. Post-transplant outcome-clusters of psychological distress and health-related quality of life in lung transplant recipients. *Swiss Med Wkly*. 2015 Dec 28;145:w14236. doi: 10.4414/sm.w.2015.14236. eCollection 2015.
99. Carbone M, Flores EG, Emi M, Johnson TA, Tsunoda T, Behner D, Hoffman H, Hesdorffer M, Nasu M, Napolitano A, Powers A, Minaai M, Baumann F, Bryant-Greenwood P, Lauk O, Kirschner MB, **Weder W**, Opitz I, Pass HI, Gaudino G, Pastorino S, Yang H. Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s. *PLoS Genet*. 2015 Dec 18;11(12):e1005633. doi: 10.1371/journal.pgen.1005633. eCollection 2015 Dec
100. Kostron A, Friess M, Cramer O, Inci I, Schneiter D, Hillinger S, Stahel R, **Weder W**, Opitz I. Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma. *Eur J Cardiothorac Surg*. 2016 May;49(5):1516-23
101. Stahel RA, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Zippelius A, Mordasini C, Caspar CB, Eckhardt K, Schmid RA, Aebbersold DM, Gautschi O, Nagel W, Töpfer M, Kraysenbuehl J, Ribi K, Ciernik IF, **Weder W**. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. *Lancet Oncol*. 2015 Dec;16(16):1651-8.
102. Baumuegger S, Hilty R, Nguyen TD, **Weder W**, Alkadhi H, Frauenfelder T. Influence of Sinogram-Affirmed Iterative Reconstruction on Computed Tomography-Based Lung Volumetry and Quantification of Pulmonary Emphysema. *J Comput Assist Tomogr*. 2016 Jan-Feb;40(1):96-101
103. Thies S, Friess M, Frischknecht L, Korol D, Felley-Bosco E, Stahel R, Vrugt B, **Weder W**, Opitz I, Soltermann A. Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis. *PLoS One*. 2015 Sep 30;10(9):e0139312. doi: 10.1371/journal.pone.0139312. eCollection 2015.
104. Leuzzi G, Rocco G, Ruffini E, Sperduti I, Detterbeck F, **Weder W**, Venuta F, Van Raemdonck D, Thomas P, Facciolo F; ESTS Thymic Working Group. Multimodality therapy for locally advanced thymomas: A propensity score-matched cohort study from the European Society of Thoracic Surgeons Database. *J Thorac Cardiovasc Surg*. 2016 Jan;151(1):47-57
105. Opitz I, Friess M, Kestenholz P, Schneiter D, Frauenfelder T, Nguyen-Kim TD, Seifert B, Hoda MA, Klepetko W, Stahel RA, **Weder W**. A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years' Experience. *J Thorac Oncol*. 2015 Nov;10(11):1634-41.
106. Pless M, Stupp R, Ris HB, Stahel RA, **Weder W**, Thierstein S, Gerard MA, Xyrafas A, Früh M, Cathomas R, Zippelius A, Roth A, Bijelovic M, Ochsenbein A, Meier UR, Mamot C, Rauch D, Gautschi O, Betticher DC, Mirimanoff RO, Peters S; SAKK Lung Cancer Project Group. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. *Lancet*. 2015 Sep 12;386(9998):1049-56.
107. Jang JH, Baerts L, Waumans Y, De Meester I, Yamada Y, Limani P, Gil-Bazo I, **Weder W**, Jungraithmayr W. Suppression of lung metastases by the CD26/DPP4 inhibitor Vildagliptin in mice. *Clin Exp Metastasis*. 2015 Oct;32(7):677-87.
108. Clarenbach CF, Sievi NA, Brock M, Schneiter D, **Weder W**, Kohler M. Lung Volume Reduction Surgery and Improvement of Endothelial Function and Blood Pressure in Patients with Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial. *Am J Respir Crit Care Med*. 2015 Aug 1;192(3):307-14.

109. Echeverry N, Ziltener G, Barbone D, **Weder W**, Stahel RA, Broaddus VC, Felley-Bosco E. Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors. *Cell Death Dis.* 2015 May 7;6:e1757. doi: 10.1038/cddis.2015.124.
110. Collaud S, Tischler V, Atanassoff A, Wiedl T, Komminoth P, Oehlschlegel C, **Weder W**, Soltermann A. Lung neuroendocrine tumors: correlation of ubiquitinylation and sumoylation with nucleo-cytosolic partitioning of PTEN. *BMC Cancer.* 2015 Feb 20;15:74.
111. Frischknecht L, Meerang M, Soltermann A, Stahel R, Moch H, Seifert B, **Weder W**, Opitz I. Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery. *J Thorac Cardiovasc Surg.* 2015 Jun;149(6):1539-46.e1.
112. Inci I, Schuurmans M, Ehram J, Schneiter D, Hillinger S, Jungraithmayr W, Benden C, **Weder W**. Lung transplantation for emphysema: impact of age on short- and long-term survival. *Eur J Cardiothorac Surg.* 2015 Dec;48(6):906-9
113. Gielis JF, Jungraithmayr W, Boulet GA, Bogers JP, **Weder W**, Cos P, Van Schil PE. A murine model of lung ischemia and reperfusion injury: tricks of the trade. *J Surg Res.* 2015 Apr;194(2):659-66.
114. Kostron A, Horn-Tutic M, Franzen D, Kestenholz P, Schneiter D, Opitz I, Kohler M, **Weder W**. Repeated lung volume reduction surgery is successful in selected patients. *Eur J Cardiothorac Surg.* 2015 Nov;48(5):710-5.
115. Rusch A, Ziltener G, Nackaerts K, **Weder W**, Stahel RA, Felley-Bosco E. Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases. *Lung Cancer.* 2015 Jan;87(1):77-9.
116. Peters S, **Weder W**, Dafni U, Kerr KM, Bubendorf L, Meldgaard P, O'Byrne KJ, Wrona A, Vansteenkiste J, Felip E, Marchetti A, Savic S, Lu S, Smit E, Dingemans AM, Blackhall FH, Baas P, Camps C, Rosell R, Stahel RA; ETOP Lungscape Investigators. Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters. *J Thorac Oncol.* 2014 Nov;9(11):1675-84.
117. Kondo K, Van Schil P, Detterbeck FC, Okumura M, Stratton K, Giroux D, Asamura H, Crowley J, Falkson C, Filosso PL, Giaccone G, Huang J, Kim J, Lucchi M, Marino M, Marom EM, Nicholson AG, Ruffini E; Staging and Prognostic Factors Committee; Members of the Advisory Boards; Participating Institutions of the Thymic Domain. The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the N and M components for the forthcoming (8th) edition of the TNM classification of malignant tumors. *J Thorac Oncol.* 2014 Sep;9(9 Suppl 2):S81-7.
118. Nicholson AG, Detterbeck FC, Marino M, Kim J, Stratton K, Giroux D, Asamura H, Crowley J, Falkson C, Filosso PL, Giaccone G, Huang J, Kondo K, Lucchi M, Marom EM, Okumura M, Ruffini E, Van Schil P; Staging and Prognostic Factors Committee; Members of the Advisory Boards; Participating Institutions of the Thymic Domain. The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the T Component for the forthcoming (8th) edition of the TNM classification of malignant tumors. *J Thorac Oncol.* 2014 Sep;9(9 Suppl 2):S73-80.
119. Detterbeck FC, Stratton K, Giroux D, Asamura H, Crowley J, Falkson C, Filosso PL, Frazier AA, Giaccone G, Huang J, Kim J, Kondo K, Lucchi M, Marino M, Marom EM, Nicholson AG, Okumura M, Ruffini E, Van Schil P; Staging and Prognostic Factors Committee; Members of the Advisory Boards; Participating Institutions of the Thymic Domain. The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. *J Thorac Oncol.* 2014 Sep;9(9 Suppl 2):S65-72.
120. Frauenfelder T, Kestenholz P, Hunziker R, Nguyen TD, Fries M, Veit-Haibach P, Husmann L, Stahel R, **Weder W**, Opitz I. Use of computed tomography and positron emission tomography/computed tomography for staging of local extent in patients with malignant pleural mesothelioma. *J Comput Assist Tomogr.* 2015 Mar-Apr;39(2):160-5.
121. Meerang M, Boss A, Kenkel D, Broggini-Tenzer A, Bérard K, Lauk O, Arni S, **Weder W**, Opitz I. Evaluation of imaging techniques for the assessment of tumour progression in an orthotopic rat model of malignant pleural mesothelioma. *Eur J Cardiothorac Surg.* 2015 Jan;47(1):e34-41

122. Filosso PL, Yao X, Ahmad U, Zhan Y, Huang J, Ruffini E, Travis W, Lucchi M, Rimner A, Antonicelli A, Guerrera F, Detterbeck F; European Society of Thoracic Surgeons Thymic Group Steering Committee. Outcome of primary neuroendocrine tumors of the thymus: a joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases. *J Thorac Cardiovasc Surg.* 2015 Jan;149(1):103-9.e2
123. Franzen D, Diebold M, Soltermann A, Schneiter D, Kestenholz P, Stahel R, **Weder W**, Kohler M. Determinants of outcome of solitary fibrous tumors of the pleura: an observational cohort study. *BMC Pulm Med.* 2014 Aug 12;14:138
124. Lauk O, Hoda MA, de Perrot M, Friess M, Klikovits T, Klepetko W, Keshavjee S, **Weder W**, Opitz I. Extrapleural pneumonectomy after induction chemotherapy: perioperative outcome in 251 mesothelioma patients from three high-volume institutions. *Ann Thorac Surg.* 2014 Nov;98(5):1748-54.
125. Pass HI, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, Asamura H, Waller D, Edwards J, **Weder W**, Hoffmann H, van Meerbeeck JP, Rusch VW; IASLC Staging Committee and Participating Institutions. Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee. *J Thorac Oncol.* 2014 Jun;9(6):856-64.
126. Ruffini E, Detterbeck F, Van Raemdonck D, Rocco G, Thomas P, **Weder W**, Brunelli A, Guerrera F, Keshavjee S, Altorki N, Schützner J, Arame A, Spaggiari L, Lim E, Toker A, Venuta F; European Society of Thoracic Surgeons Thymic Working Group. Thymic carcinoma: a cohort study of patients from the European society of thoracic surgeons database. *J Thorac Oncol.* 2014 Apr;9(4):541-8.
127. Kerr KM, Bubendorf L, Edelman MJ, Marchetti A, Mok T, Novello S, O'Byrne K, Stahel R, Peters S, Felip E; Panel Members; Panel Members. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. *Ann Oncol.* 2014 Sep;25(9):1681-90
128. Besse B, Adjei A, Baas P, Meldgaard P, Nicolson M, Paz-Ares L, Reck M, Smit EF, Syrigos K, Stahel R, Felip E, Peters S; Panel Members; ESMO. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. *Ann Oncol.* 2014 Aug;25(8):1475-84
129. Otterstrom C, Soltermann A, Opitz I, Felley-Bosco E, **Weder W**, Stahel RA, Triponez F, Robert JH, Serre-Beinier V. CD74: a new prognostic factor for patients with malignant pleural mesothelioma. *Br J Cancer.* 2014 Apr 15;110(8):2040-6.
130. Pison C, Magnan A, Botturi K, Sève M, Brouard S, Marsland BJ, Ernst F, Paprotka T, Deplanche K, Fritz A, Siroux V, Boissel JP, Corris PA, Auffray C, Nicod LP; SysCLAD consortium. Prediction of chronic lung allograft dysfunction: a systems medicine challenge. *Eur Respir J.* 2014 Mar;43(3):689-93
131. Vansteenkiste J, Crinò L, Doooms C, Douillard JY, Faivre-Finn C, Lim E, Rocco G, Senan S, Van Schil P, Veronesi G, Stahel R, Peters S, Felip E; Panel Members. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. *Ann Oncol.* 2014 Aug;25(8):1462-74.
132. Ruffini E, Detterbeck F, Van Raemdonck D, Rocco G, Thomas P, **Weder W**, Brunelli A, Evangelista A, Venuta F; European Association of Thoracic Surgeons (ESTS) Thymic Working Group. Tumours of the thymus: a cohort study of prognostic factors from the European Society of Thoracic Surgeons database. *Eur J Cardiothorac Surg.* 2014 Sep;46(3):361-8
133. Frauenfelder T, Puhan MA, Lazor R, von Garnier C, Bremerich J, Niemann T, Christe A, Montet X, Gautschi O, **Weder W**, Kohler M; expert panel. Early detection of lung cancer: a statement from an expert panel of the Swiss university hospitals on lung cancer screening. *Respiration.* 2014;87(3):254-64.
134. Bitanirwe BK, Meerang M, Friess M, Soltermann A, Frischknecht L, Thies S, Felley-Bosco E, Tsao MS, Allo G, de Perrot M, Seifert B, Moch H, Stahel R, **Weder W**, Opitz I. PI3K/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy. *J Thorac Oncol.* 2014 Feb;9(2):239-47.
135. Detterbeck FC, Asamura H, Crowley J, Falkson C, Giaccone G, Giroux D, Huang J, Kim J, Kondo K, Lucchi M, Marino M, Marom EM, Nicholson A, Okumura M, Ruffini E, van Schil P, Stratton K; Staging and Prognostic Factors Committee; Members of the Advisory Boards; Participating Institutions of the Thymic

Domain. The IASLC/ITMIG thymic malignancies staging project: development of a stage classification for thymic malignancies. *J Thorac Oncol*. 2013 Dec;8(12):1467-73

136. Jungraithmayr W, Laube I, Hild N, Stark WJ, Mihic-Probst D, **Weder W**, Buschmann J. Bioactive nanocomposite for chest-wall replacement: Cellular response in a murine model. *J Biomater Appl*. 2014 Jul;29(1):36-45.
137. Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors. *Sci Transl Med*. 2013 Oct 30;5(209):209ra153. doi: 10.1126/scitranslmed.3006802.
138. Zuercher AJ, Inci I, Benden C, Fretz G, Béchir M, Boehler A, **Weder W**. Intra-operative extracorporeal membrane oxygenation use in pediatric lung transplantation—the Zurich experience. *Pediatr Transplant*. 2013 Dec;17(8):800-5
139. Tsushima Y, Jang JH, Yamada Y, Schwendener R, Suzuki K, **Weder W**, Jungraithmayr W. The depletion of donor macrophages reduces ischaemia-reperfusion injury after mouse lung transplantation. *Eur J Cardiothorac Surg*. 2014 Apr;45(4):703-9.
140. Inci I, Schuurmans MM, Boehler A, **Weder W**. Zurich University Hospital lung transplantation programme: update 2012. *Swiss Med Wkly*. 2013 Aug 22;143:w13836. doi: 10.4414/smw.2013.13836.
141. Tsushima Y, Jang JH, Wurnig MC, Boss A, Suzuki K, **Weder W**, Jungraithmayr W. Mastering mouse lung transplantation from scratch—a track record. *J Surg Res*. 2013 Nov;185(1):426-32
142. Inci I, Hillinger S, Arni S, Kaplan T, Inci D, **Weder W**. Reconditioning of an injured lung graft with intrabronchial surfactant instillation in an ex vivo lung perfusion system followed by transplantation. *J Surg Res*. 2013 Oct;184(2):1143-9
143. Jungraithmayr W, Codarri L, Bouchaud G, Krieg C, Boyman O, Gyölvézi G, Becher B, **Weder W**, Münz C. Cytokine complex-expanded natural killer cells improve allogeneic lung transplant function via depletion of donor dendritic cells. *Am J Respir Crit Care Med*. 2013 Jun 15;187(12):1349-59.
144. Opitz I, Arni S, Oberreiter B, Asmis LM, Vogt P, Rousson V, **Weder W**, Lardinois D. Perioperative diclofenac application during video-assisted thoracic surgery pleurodesis modulates early inflammatory and fibrinolytic processes in an experimental model. *Eur Surg Res*. 2013;50(1):14-23.
145. Rusch V, Baldini EH, Bueno R, De Perrot M, Flores R, Hasegawa S, Klepetko W, Krug L, Lang-Lazdunski L, Pass H, **Weder W**, Sugarbaker DJ; participants in 2012 International Mesothelioma Interest Group Congress. The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, Mass. *J Thorac Cardiovasc Surg*. 2013 Apr;145(4):909-10.
146. Erne BV, Jungraithmayr W, Buschmann J, Arni S, **Weder W**, Inci I. Effect of N-acetylcysteine on acute allograft rejection after rat lung transplantation. *Ann Thorac Surg*. 2013 Mar;95(3):1021-7.
147. Inci I, Hillinger S, Arni S, Jungraithmayr W, Inci D, Vogt P, Leskosek B, Hansen G, **Weder W**. Surfactant improves graft function after gastric acid-induced lung damage in lung transplantation. *Ann Thorac Surg*. 2013 Mar;95(3):1013-9.
148. Petrausch U, Schuberth PC, Hagedorn C, Soltermann A, Tomaszek S, Stahel R, **Weder W**, Renner C. Redirected T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1). *BMC Cancer*. 2012 Dec 22;12:615.
149. Wulf MA, Bode B, Zimmermann D, Rufibach K, **Weder W**, Moch H, Soltermann A, Tischler V. Silver-enhanced in situ hybridization for determination of EGFR copy number alterations in non-small cell lung cancer. *Am J Surg Pathol*. 2012 Dec;36(12):1801-8.
150. Inci I, Schuurmans MM, Kestenholz P, Schneiter D, Hillinger S, Opitz I, Boehler A, **Weder W**. Long-term outcomes of bilateral lobar lung transplantation. *Eur J Cardiothorac Surg*. 2013 Jun;43(6):1220-5.
151. Rusch VW, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, Pass H, Asamura H, Waller D, Edwards J, **Weder W**, Hoffmann H, van Meerbeeck JP; IASLC Staging Committee. Initial analysis of the international association for the study of lung cancer mesothelioma database. *J Thorac Oncol*. 2012 Nov;7(11):1631-9.

152. Jungraithmayr W, Chuck N, Frauenfelder T, **Weder W**, Boss A. MR imaging by using very short echo-time sequences after syngeneic lung transplantation in mice. *Radiology*. 2012 Dec;265(3):753-61.
153. Collaud S, Stahel R, Inci I, Hillinger S, Schneiter D, Kestenholz P, **Weder W**. Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage. *Lung Cancer*. 2012 Dec;78(3):234-8.
154. Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Müller C, Di Cerbo V, Schildhaus HU, Altmüller J, Baessmann I, Becker C, de Wilde B, Vandesompele J, Böhm D, Ansén S, Gabler F, Wilkening I, Heynck S, Heuckmann JM, Lu X, Carter SL, Cibulskis K, Banerji S, Getz G, Park KS, Rauh D, Grütter C, Fischer M, Pasqualucci L, Wright G, Wainer Z, Russell P, Petersen I, Chen Y, Stoelben E, Ludwig C, Schnabel P, Hoffmann H, Muley T, Brockmann M, Engel-Riedel W, Muscarella LA, Fazio VM, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman DA, Snijders PJ, Cappuzzo F, Ligorio C, Damiani S, Field J, Solberg S, Brustugun OT, Lund-Iversen M, Sängler J, Clement JH, Soltermann A, Moch H, **Weder W**, Solomon B, Soria JC, Validire P, Besse B, Brambilla E, Brambilla C, Lantuejoul S, Lorimier P, Schneider PM, Hallek M, Pao W, Meyerson M, Sage J, Shendure J, Schneider R, Büttner R, Wolf J, Nürnberg P, Perner S, Heukamp LC, Brindle PK, Haas S, Thomas RK. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. *Nat Genet*. 2012 Oct;44(10):1104-10.
155. Schneiter D, Tomaszek S, Kestenholz P, Hillinger S, Opitz I, Inci I, **Weder W**. Minimally invasive resection of thymomas with the da Vinci® Surgical System. *Eur J Cardiothorac Surg*. 2013 Feb;43(2):288-92
156. Shi Y, Moura U, Opitz I, Soltermann A, Rehrauer H, Thies S, **Weder W**, Stahel RA, Felley-Bosco E. Role of hedgehog signaling in malignant pleural mesothelioma. *Clin Cancer Res*. 2012 Sep 1;18(17):4646-56.
157. Jungraithmayr W, **Weder W**. The technique of orthotopic mouse lung transplantation as a movie-improved learning by visualization. *Am J Transplant*. 2012 Jun;12(6):1624-6.
158. Storelli E, Tutic M, Kestenholz P, Schneiter D, Opitz I, Hillinger S, **Weder W**. Sleeve resections with unprotected bronchial anastomoses are safe even after neoadjuvant therapy. *Eur J Cardiothorac Surg*. 2012 Jul;42(1):77-81.
159. Jungraithmayr W, De Meester I, Matheeußen V, Baerts L, Arni S, **Weder W**. CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation. *Eur J Cardiothorac Surg*. 2012 May;41(5):1166-73.
160. Collaud S, Lardinois D, Tischler V, Steinert HC, Stahel R, **Weder W**. Significance of a new fluorodeoxyglucose-positive lesion on restaging positron emission tomography/computed tomography after induction therapy for non-small-cell lung cancer. *Eur J Cardiothorac Surg*. 2012 Mar;41(3):612-6.
161. Wiedl T, Collaud S, Hillinger S, Arni S, Burgess C, Kroll W, Schraml P, Soltermann A, Moch H, **Weder W**. KRAS mutation is associated with elevated myeloblastin activity in human lung adenocarcinoma. *Cancer Genomics Proteomics*. 2012 Jan;9(1):51-4.
162. Jungraithmayr W, Draenert A, Marquardt K, **Weder W**. Ultrastructural changes in acute lung allograft rejection: novel insights from an animal study. *J Heart Lung Transplant*. 2012 Jan;31(1):94-100
163. Hofer M, Schmid C, Benden C, Speich R, Inci I, **Weder W**, Boehler A. Diabetes mellitus and survival in cystic fibrosis patients after lung transplantation. *J Cyst Fibros*. 2012 Mar;11(2):131-6.

Case reports

1. Hodel L, Inci I, Schanz U, Vrugt B, **Weder W**, Hillinger S. Urokinase application for hemothorax in pulmonary mucormycosis. *J Thorac Dis*. 2018 Mar;10(3):E175-E178.
2. Robinson CA, Inci I, Naegeli M, Murer C, Schuurmans MM, Urosevic-Maiwald M, Schüpbach R, **Weder W**, Benden C. Extracorporeal photopheresis as second-line treatment therapy in life-threatening primary graft dysfunction following lung transplantation. *Pediatr Transplant*. 2018 Jan 29. doi: 10.1111/ptr.13145. [Epub ahead of print]

3. Jungraithmayr W, Leggeri E, **Weder W**, Vrugt B. Sarcoidosis as a rare cause for symmetrical giant bullous disease. *BMC Pulm Med.* 2017 May 30;17(1):88.
4. Büyükakyüz N, Hillinger S, **Weder W**, Jungraithmayr W. Bronchopulmonary carcinoid with a single lymph node metastasis causing ectopic Cushing's syndrome. *J Thorac Dis.* 2017 Mar;9(3):E194-E196.
5. Caviezel C, Koersgen F, **Weder W**, Inci I. Left main bronchus sleeve resection with reconstruction of neolobar carina. *J Thorac Cardiovasc Surg.* 2017 Jul;154(1):370-372.
6. Schuurmans MM, Benden C, Moehrlen C, Gubler C, Wilhelm M, **Weder W**, Inci I. Esophagopericardial fistula, septic shock and intracranial hemorrhage with hydrocephalus after lung transplantation. *Rev Port Pneumol (2006).* 2017 May - Jun;23(3):156-159
7. Tan Q, Liu R, Chen X, Wu J, Pan Y, Lu S, **Weder W**, Luo Q. Clinic application of tissue engineered bronchus for lung cancer treatment. *J Thorac Dis.* 2017 Jan;9(1):22-29.
8. Tzafos S, Collaud S, Wilhelm M, Wieser S, **Weder W**, Inci I. Lung Volume Reduction Surgery on Extracorporeal Life Support. *Ann Thorac Surg.* 2017 Feb;103(2):e115-e117.
9. Scaglioni MF, Lindenblatt N, Barth AA, Fuchs B, **Weder W**, Giovanoli P. Free fillet flap application to cover forequarter or traumatic amputation of an upper extremity: A case report. *Microsurgery.* 2016 Nov;36(8):700-704
10. Brüstle K, Lema S, Komminoth P, **Weder W**, Vrugt B, Jungraithmayr W. Placental transmogrification of the lung presenting as progressive symptomatic bullous emphysema. *Thorax.* 2017 Mar;72(3):284-285
11. Jungraithmayr W, Tzafos S, Distler O, Kolios AG, **Weder W**, Franzen D. Rapid Growth of Lung Nodules due to Combined Pulmonary Vasculitis, Silicoanthracosis, and Chondrocalcinosis. *Can Respir J.* 2016;2016:9254374. doi: 10.1155/2016/9254374. Epub 2016 Jul 10.
12. Schweckendiek D, Inci I, Schneiter D, **Weder W**. Inflammatory Myofibroblastic Tumor of the Lung: Two Progressing Pulmonary Nodules in a 25-Year-Old Adult With a *Moraxella catharalis* Infection. *Ann Thorac Surg.* 2015 Dec;100(6):e123-4.
13. Inci I, Yamada Y, Hillinger S, Jungraithmayr W, Trinkwitz M, **Weder W**. Successful lung transplantation after donor lung reconditioning with urokinase in ex vivo lung perfusion system. *Ann Thorac Surg.* 2014 Nov;98(5):1837-8.
14. Renner TA, Zalunardo MP, **Weder W**, Spahn DR. Bilateral lung transplantation in a patient receiving rivaroxaban anticoagulation. *J Cardiothorac Vasc Anesth.* 2015;29(3):723-6.
15. Jungraithmayr W, Delaloye-Frischknecht B, **Weder W**. Anthracotic intrapulmonary lymph nodes mimicking lung metastases. *Ann Thorac Surg.* 2014 Aug;98(2):704-6.
16. Inci I, Soltermann A, Schneiter D, **Weder W**. Pulmonary malignant peripheral nerve sheath tumour. *Eur J Cardiothorac Surg.* 2014 Aug;46(2):331-2.
17. Inci I, Benden C, Kestenholz P, Hillinger S, Schneiter D, Ganter M, Bechir M, Grünenfelder J, **Weder W**. Simultaneous bilateral lobar lung transplantation: one donor serves two recipients. *Ann Thorac Surg.* 2013 Sep;96(3):e69-71.
18. Leisibach P, **Weder W**, Soltermann A, Jungraithmayr W. Primary sclerosing epithelioid fibrosarcoma of the lung in a patient with Lynch syndrome. *Lung.* 2012 Dec;190(6):691-5
19. von Boehmer L, Draenert A, Jungraithmayr W, Inci I, Niklaus S, Boehler A, Hofer M, Stahel R, Soltermann A, van den Broek M, **Weder W**, Knuth A. Immunosuppression and lung cancer of donor origin after bilateral lung transplantation. *Lung Cancer.* 2012 Apr;76(1):118-22

Reviews

1. Lacour M, Caviezel C, **Weder W**, Schneiter D. Postoperative complications and management after lung volume reduction surgery. *J Thorac Dis.* 2018 Aug;10(Suppl 23):S2775-S2779. doi: 10.21037/jtd.2018.08.75. Review.

2. Caviezel C, Schneiter D, Opitz I, **Weder W**. Lung volume reduction surgery beyond the NETT selection criteria. *J Thorac Dis*. 2018 Aug;10(Suppl 23):S2748-S2753. doi: 10.21037/jtd.2018.08.93. Review.
3. Franzen DP, **Weder W**. Lung volume reduction-a great chance for emphysema patients! *J Thorac Dis*. 2018 Aug;10(Suppl 23):S2696-S2697. doi: 10.21037/jtd.2018.04.144. No abstract available.
4. Inci I, Hillinger S, Schneiter D, Opitz I, Schuurmans M, Benden C, **Weder W**. Lung Transplantation with Controlled Donation after Circulatory Death Donors. *Ann Thorac Cardiovasc Surg*. 2018 Jul 2. doi: 10.5761/atcs.oa.18-00098. [Epub ahead of print]
5. Opitz I, **Weder W**. Pleural mesothelioma: is the surgeon still there? *Ann Oncol*. 2018 Jun 14. doi: 10.1093/annonc/mdy195. [Epub ahead of print]
6. Caviezel C, Franzen D, **Weder W**. [Lung Volume Reduction Surgery]. *Pneumologie*. 2018 Jan;72(1):64-78.
7. **Weder W**, Moghanaki D, Stiles B, Siva S, Rocco G. The great debate flashes: Surgery versus stereotactic body radiotherapy as the primary treatment of early-stage lung cancer. *Eur J Cardiothorac Surg*. 2017 Dec 21. doi: 10.1093/ejcts/ezx410. [Epub ahead of print]
8. Opitz I, **Weder W**. A nuanced view of extrapleural pneumonectomy for malignant pleural mesothelioma. *Ann Transl Med*. 2017 Jun;5(11):237.
9. **Weder W**, Inci I. Carinal resection and sleeve pneumonectomy. *J Thorac Dis*. 2016 Nov;8(Suppl 11):S882-S888
10. Collaud S, Benden C, Ganter C, Hillinger S, Opitz I, Schneiter D, Schuepbach R, Inci I, **Weder W**. Extracorporeal Life Support as Bridge to Lung Retransplantation: A Multicenter Pooled Data Analysis. *Ann Thorac Surg*. 2016 Nov;102(5):1680-1686
11. Caviezel C, Franzen D, Inci I, **Weder W**. [Lung Volume Reduction Surgery - State of the Art 2016]. *Zentralbl Chir*. 2016 Sep;141 Suppl 1:S26-34.
12. Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, **Weder W**, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA Jr, Mok TS, Hirsch FR. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. *J Thorac Oncol*. 2016 Jul;11(7):946-63
13. Opitz I, **Weder W**. Induction Therapy for Mesothelioma. *Semin Thorac Cardiovasc Surg*. 2015 Summer;27(2):240-9.
14. Inci I, Klinzing S, Schneiter D, Schuepbach RA, Kestenholz P, Hillinger S, Benden C, Maggiorini M, **Weder W**. Outcome of Extracorporeal Membrane Oxygenation as a Bridge To Lung Transplantation: An Institutional Experience and Literature Review. *Transplantation*. 2015 Aug;99(8):1667-71.
15. Eberhardt WE, De Ruyscher D, **Weder W**, Le Péchoux C, De Leyn P, Hoffmann H, Westeel V, Stahel R, Felip E, Peters S; Panel Members. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. *Ann Oncol*. 2015 Aug;26(8):1573-88
16. De Leyn P, Doooms C, Kuzdzal J, Lardinois D, Passlick B, Rami-Porta R, Turna A, Van Schil P, Venuta F, Waller D, **Weder W**, Zielinski M. Preoperative mediastinal lymph node staging for non-small cell lung cancer: 2014 update of the 2007 ESTS guidelines. *Transl Lung Cancer Res*. 2014 Aug;3(4):225-33
17. Stahel RA, **Weder W**, Felley-Bosco E, Petrausch U, Curioni-Fontecedro A, Schmitt-Opitz I, Peters S. Searching for targets for the systemic therapy of mesothelioma. *Ann Oncol*. 2015 Aug;26(8):1649-60.
18. Henzler T, Goldstraw P, Wenz F, Pirker R, **Weder W**, Apfaltrer P, Meyer M, Buesing K, Crino L, Fennell D, Fink C, Grunenwald D, Manegold C, Pilz L, Schoenberg SO, Suresh S, Vansteenkiste J, Voigt W, Wängler B, Schmid-Bindert G. Perspectives of novel imaging techniques for staging, therapy response assessment, and monitoring of surveillance in lung cancer: summary of the Dresden 2013 Post WCLC-IASLC State-of-the-Art Imaging Workshop. *J Thorac Oncol*. 2015 Feb;10(2):237-49
19. Van Schil PE, Opitz I, **Weder W**, De Laet C, Domen A, Lauwers P, Hendriks JM, Van Meerbeeck JP. Multimodal management of malignant pleural mesothelioma: where are we today? *Eur Respir J*. 2014 Sep;44(3):754-64

20. **Weder W**, Inci I. Carinal resection and sleeve pneumonectomy. *Thorac Surg Clin*. 2014 Feb;24(1):77-83.
21. **Weder W**, Opitz I. Multimodality therapy for malignant pleural mesothelioma. *Ann Cardiothorac Surg*. 2012 Nov;1(4):502-7.
22. Rocco G, **Weder W**. Lung surgery in the elderly today. *Lung Cancer*. 2013 May;80(2):115-9
23. Jungraithmayr W, Jang JH, Schrepfer S, Inci I, **Weder W**. Small animal models of experimental obliterative bronchiolitis. *Am J Respir Cell Mol Biol*. 2013 Jun;48(6):675-84
24. **Weder W**. Advances in surgery. *Ann Oncol*. 2012 Sep;23 Suppl 10:x43-5.
25. Schneider D, **Weder W**. [Minimal-invasive surgery for lung cancer - strategies and limits]. *Ther Umsch*. 2012 Jul;69(7):406-10
26. Opitz I, **Weder W**. [Malignant pleural mesothelioma]. *Ther Umsch*. 2012 Jul;69(7):401-5.
27. Jungraithmayr W, **Weder W**. Chest surgical disorders in ancient Egypt: evidence of advanced knowledge. *Ann Surg*. 2012 Mar;255(3):605-8.

Guidelines

1. Opitz I, Scherpereel A, Berghmans T, Psallidas I, Glatzer M, Rigau D, Astoul P, Bölükbas S, Boyd J, Coolen J, De Bondt C, De Ruysscher D, Durieux V, Faivre-Finn C, Fennell DA, Galateau-Salle F, Greillier L, Hoda MA, Klepetko W, Lacourt A, McElnay P, Maskell NA, Mutti L, Paireon JC, Van Schil P, van Meerbeeck JP, Waller D, **Weder W**, Putora PM, Cardillo G. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. *Eur J Cardiothorac Surg*. 2020 Jul 1;58(1):1-24. doi: 10.1093/ejcts/ezaa158. PMID: 32448904.
2. Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, Astoul P, Bölükbas S, Boyd J, Coolen J, De Bondt C, De Ruysscher D, Durieux V, Faivre-Finn C, Fennell D, Galateau-Salle F, Greillier L, Hoda MA, Klepetko W, Lacourt A, McElnay P, Maskell NA, Mutti L, Paireon JC, Van Schil P, van Meerbeeck JP, Waller D, **Weder W**, Cardillo G, Putora PM. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. *Eur Respir J*. 2020 Jun 11;55(6):1900953. doi: 10.1183/13993003.00953-2019. PMID: 32451346.
3. De Leyn P, Doooms C, Kuzdzal J, Lardinois D, Passlick B, Rami-Porta R, Turna A, Van Schil P, Venuta F, Waller D, **Weder W**, Zielinski M. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. *Eur J Cardiothorac Surg*. 2014 May;45(5):787-98.

Correspondence and Comments

1. Guckenberger M, Aerts JG, Van Schil P, **Weder W**. The American Society of Clinical Oncology-endorsed American Society for Radiation Oncology Evidence-Based Guideline of stereotactic body radiotherapy for early-stage non-small cell lung cancer: An expert opinion. *J Thorac Cardiovasc Surg*. 2019 Jan;157(1):358-361. doi: 10.1016/j.jtcvs.2018.09.107. Epub 2018 Oct 12. No abstract available. Erratum in: *J Thorac Cardiovasc Surg*. 2019 Mar 25;:.
2. **Weder W**. Antwort. *Pneumologie*. 2018 Apr;72(4):321.
3. Rocco G, **Weder W**. What's happening next. *J Thorac Cardiovasc Surg*. 2018 Apr;155(4):1781-1782.
4. Franzen D, **Weder W**. Lung volume reduction for emphysema. *Lancet Respir Med*. 2017 Jul;5(7):e23.
5. Opitz I, **Weder W**. Clinical Relevance of Our Multimodality Prognostic Score. *J Thorac Oncol*. 2016 Mar;11(3):e39-40.
6. Riesterer O, **Weder W**, Stahel R. Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power? - Authors' reply. *Lancet Oncol*. 2016 Feb;17(2):e44-e45.
7. Jungraithmayr W, Brüstle K, **Weder W**. Harnessing regulatory B cells to prevent experimental obliterative bronchiolitis. *J Thorac Cardiovasc Surg*. 2016 Feb;151(2):497-8.

8. Lim E, McElnay PJ, Rocco G, Brunelli A, Massard G, Toker A, Passlick B, Varela G, **Weder W**. Invasive mediastinal staging is irrelevant for PET/CT positive N2 lung cancer if the primary tumour and ipsilateral lymph nodes are resectable. *Lancet Respir Med*. 2015 Sep;3(9):e32-e33
9. Opitz I, Rocco G, Brunelli A, Varela G, Massard G, **Weder W**; European Society of Thoracic Surgeons. Surgery versus SABR for resectable non-small-cell lung cancer. *Lancet Oncol*. 2015 Aug;16(8):e372-3.
10. Inci I, **Weder W**. Reply to Eberlein et al. *Eur J Cardiothorac Surg*. 2013 Aug;44(2):395-6.

Book Chapters

1. **Weder W** and Opitz I. Induction Chemotherapy Followed by surgery for Malignant Pleural Mesothelioma. *Adult Chest Surgery, Second Edition*, McGraw-Hill. 2015
2. **Weder W** and Opitz I. Malignant Pleural Mesothelioma – the Multimodality Approach.